Author

I. Paciello

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 9

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Organism:human· 7 Research Focus:host-pathogen & immune response· 5 Assay:proteomics· 5 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

E. Andreano· 8 shared R. Rappuoli· 8 shared C. Sala· 7 shared E. Montomoli· 7 shared E. Pantano· 7 shared G. Piccini· 7 shared N. Manganaro· 6 shared P. Pileri· 6 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersImmunology

E. Andreano

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens

M. Troisi, M. Fabbrini, S. Stazzoni, V. Viviani, F. Carboni, V. Abbiento, L. E. Fontana, S. Tomei, M. Audagnotto, L. Santini, A. Spagnuolo, G. Antonelli, I. Paciello, F. Vacca, D. Cardamone, , An

The paper identifies human monoclonal antibodies that recognize key antigens, PorB and LOS, providing cross-protection against gonococcal and meningococcal infections.

bioRxiv · Dec 7, 2023 · PreprintImmunology

High-resolution map of the Fc-functions mediated by COVID-19 neutralizing antibodies

I. Paciello, G. Maccari, E. Pantano, E. Andreano, R. Rappuoli

This study maps Fc-functions of 482 SARS-CoV-2 neutralizing antibodies, showing that potent neutralizers may have weak Fc-functions and that Fc-functions are influenced by epitope targeting and B cell germlines.

bioRxiv · Jul 10, 2023Immunology

mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5

E. Andreano, I. Paciello, G. Pierleoni, G. Maccari, G. Antonelli, V. Abbiento, P. Pileri, L. Benincasa, G. Giglioli, G. Piccini, C. De Santi, C. Sala, D. Medini, E. Montomoli, P. Maes, R. Rappuoli

The paper compares neutralizing antibodies against Omicron BA.4 and BA.5 from mRNA-vaccinated individuals and those with hybrid immunity, finding differences in epitope targeting and B cell germlines used.

bioRxiv · Aug 4, 2022 · PreprintImmunology

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

J. L. Torres, G. Ozorowski, E. Andreano, H. Liu, J. Copps, G. Piccini, L. Donnici, M. Conti, C. Planchais, D. Planas, N. Manganaro, E. Pantano, I. Paciello, P. Pileri, T. Bruel, , A. B. Ward

The paper evaluates the potency of mAb J08 against SARS-CoV-2 variants using cell-based assays and cryo-EM, showing its resistance to escape mutations and broad binding capability.

Proceedings of the National Academy of Sciences · May 12, 2022Peer-reviewedImmunology

COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response

E. Andreano, I. Paciello, G. Pierleoni, G. Piccini, V. Abbiento, G. Antonelli, P. Pileri, N. Manganaro, E. Pantano, G. Maccari, S. Marchese, L. Donnici, L. Benincasa, G. Giglioli, M. Leonardi, , R. Rappuoli

This study examines how a third mRNA vaccine dose enhances neutralizing antibody responses against SARS-CoV-2 variants by expanding specific B cell germlines and altering the antibody repertoire.

bioRxiv · May 9, 2022 · PreprintImmunology

Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and variants of concern

E. Andreano, I. Paciello, G. Piccini, N. Manganaro, P. Pileri, I. Hyseni, M. Leonardi, E. Pantano, V. Abbiento, L. Benincasa, G. Giglioli, C. De Santi, M. Fabbiani, I. Rancan, M. Tumbarello, , R. Rappuoli

This study compares B cell responses in naive and convalescent individuals after SARS-CoV-2 vaccination, showing convalescents have higher frequency and broader neutralizing antibody responses against variants.

bioRxiv · Aug 12, 2021 · PreprintImmunology

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

E. Andreano, G. Piccini, D. Licastro, L. Casalino, N. V. Johnson, I. Paciello, S. Dal Monego, E. Pantano, N. Manganaro, A. Manenti, R. Manna, E. Casa, I. Hyseni, L. Benincasa, E. Montomoli, , R. Rappuoli

This study shows that three mutations in SARS-CoV-2 allowed it to escape neutralization by a highly neutralizing convalescent plasma.

bioRxiv · Dec 28, 2020Immunology

Extremely potent human monoclonal antibodies from convalescent Covid-19 patients

E. Andreano, E. Nicastri, I. Paciello, P. Pileri, N. Manganaro, G. Piccini, A. Manenti, E. Pantano, A. Kabanova, M. Troisi, F. Vacca, D. Cardamone, C. De Santi, L. Benincasa, C. Agrati, , R. Rappuoli

The paper isolates extremely potent human monoclonal antibodies from convalescent Covid-19 patients, effective against SARS-CoV-2 at low concentrations.

bioRxiv · Oct 7, 2020Immunology

Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients

E. Andreano, E. Nicastri, I. Paciello, P. Pileri, N. Manganaro, G. Piccini, A. Manenti, M. Troisi, F. Vacca, E. Pantano, C. De Santi, D. Cardamone, A. Kabanova, C. Agrati, C. Castilletti, , R. Rappuoli

The paper isolates neutralizing human monoclonal antibodies from Covid-19 convalescent patients for therapeutic and prophylactic interventions.

bioRxiv · May 5, 2020 · PreprintImmunology